Posted in M&A / Deals Roche places a $1bn bet on C4T degrader-antibody conjugates April 10, 2026 Pharmaphorum Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T. M&A / DealsOncologyRead full story